In his State of the Union address, President Trump claimed to have raised the cost of prescription drugs in the US from the highest in the world to the lowest.[1] Novo Nordisk announced that it will reduce the list prices of its weight loss and diabetes drugs Wegovy, Ozempic, and Rybelsus to $675 per month starting in January 2027, a reduction of up to 50% from the original prices of approximately $1,350 for Wegovy and $1,000 for Ozempic and Rybelsus.[1] This reduction may help patients with high copays or high deductible policies because it is calculated from the list price.[1] However, the change will not affect the net price that insurance companies pay after discounts, or the cash payments of uninsured patients.[1] The company entered into an agreement with US startup Vivtex to develop oral biologics against obesity and diabetes, where Vivtex can receive up to $2.1 billion plus royalties.[2][3] Vivtex was founded in 2018 by MIT scientists including Robert Langer, Giovanni Travers, and Thomas von Erlach.[2][3] Novo Nordisk already launched the first oral biologic Rybelsus for diabetes in 2019, and they approved an oral form of Wego at the end of 2025.[2]